Buying

Compounded peptides: what they are, and which are legal

Made by a licensed pharmacy, on a prescription, from an ingredient FDA allows. Here is what compounded peptides are, which ones are legal to compound in 2026, and what a research-labelled vial is not.

20 November 2026 7 min read By Peptide AI Editorial policy

Compounded peptides are peptide preparations made by a licensed pharmacy, usually for one patient on a prescription, rather than manufactured under an FDA approval. They are not FDA-approved drugs, and they are legal only when the pharmacy works from an ingredient FDA treats as eligible. Most peptides people ask about, BPC-157 and TB-500 among them, are not eligible today.

The word gets stretched online. A pharmacy-made vial on a prescription, a telehealth "peptide program" and a research-labelled powder can all be called compounded peptides, and only the first is what the law means. This page sets out what the term covers, which compounded peptides a pharmacy can make in 2026, where HHS's October 2026 draft policy fits, and how to check a pharmacy before you buy. It is general information, not legal or medical advice, it covers the United States only, and it does not name or rank any pharmacy or seller.

The short version

  • Compounded means pharmacy-made. A 503A pharmacy makes it for one patient on a prescription. A 503B outsourcing facility makes batches under FDA registration.
  • Compounded peptides are not FDA-approved. That follows from the category, and it means no regulator has reviewed one for the use it is prescribed for.
  • Eligibility decides what exists. A 503A pharmacy needs an ingredient that is part of an approved drug, has a USP monograph, or is on FDA's 503A bulks list. No popular research peptide is on that list.
  • Six peptides have a draft route. HHS's October 2026 draft policy covers BPC-157, TB-500, MOTS-c and three others. It is a draft, and it does not cover research-use-only vials.
  • Research-use-only is not compounded. A vial sold online for laboratory use comes from no pharmacy and no prescription.

What are compounded peptides?

Compounding is a pharmacy combining or altering ingredients to make a medication for a patient. It exists for cases approved products do not cover: a dose that is not manufactured, a formulation without an allergen, a drug in shortage. A compounded peptide is that process applied to a peptide ingredient. Our compounded medication glossary entry goes through the category in full.

Two kinds of compounder make them, and the difference decides the oversight.

SourceWho oversees itHow it makes the productWhat to check
503A compounding pharmacyMainly the state board of pharmacy. Not required to follow current good manufacturing practice.For one identified patient, against a prescription, from an eligible bulk ingredient.The pharmacy's license on your state board of pharmacy, and the eligibility route for the ingredient.
503B outsourcing facilityRegistered with FDA, inspected, and required to follow good manufacturing practice and report adverse events.In batches, usually for clinics and hospitals, from a different ingredient list.That the facility appears on FDA's list of registered outsourcing facilities.
"Research use only" sellerNo drug regulator. Sold as a laboratory reagent.Not compounded at all. No pharmacy, no prescription.An independent test of your own lot. A test does not make it fit for people.

Are compounded peptides FDA approved?

A compounded preparation is not an FDA-approved drug, whoever makes it. Approval attaches to a specific product made by a specific manufacturer, and a compounded preparation is made to order.

That has practical effects. At FDA's July 2026 committee meeting, the acting director of its Office of Compounding Quality and Compliance set out what applies to a 503A product: it "is not FDA approved", it "is not required to have a label to inform patients and providers how to use it", and 503A compounders "are not required to report adverse events" to FDA. There is no approved labelling with trial-derived dosing, contraindications or interactions, and batch-to-batch variation is a live concern where good manufacturing practice does not apply. The 503A bulks list explained page quotes the full slide.

A compounded vial is also not a generic. FDA has said companies cannot call a compounded product a generic version of an approved drug.

Are compounded peptides legal?

Yes, when three things line up: a licensed pharmacy, a prescription for an identified patient, and an eligible ingredient. The third is where most peptides fall out. Under section 503A, a bulk ingredient qualifies when it:

  • meets a United States Pharmacopeia monograph, if one exists; or
  • is a component of an FDA-approved drug, if no monograph exists; or
  • is on the 503A bulks list, which FDA builds through rulemaking.

Most peptides discussed online have no monograph and are not part of any approved drug, so the bulks list is their only route. At our last check, on 15 October 2026, FDA had not published a rule adding any peptide to it. Here is where the best-known ones stand.

PeptideCan a 503A pharmacy compound it today?Why
Semaglutide, tirzepatideOnly in narrow cases.Approved drugs. Copies were allowed while they were in shortage. FDA declared the tirzepatide shortage resolved on 19 December 2024 and the semaglutide shortage on 21 February 2025.
BPC-157, TB-500, MOTS-cNot yet. A draft would allow it.Off Category 2 after their nominations were withdrawn, and recommended by FDA's advisory committee in July 2026. Not on the bulks list. Covered by HHS's October 2026 draft policy.
KPV, Semax, EpitalonNot while they stay off the list.Off Category 2 after their nominations were withdrawn, and recommended by the same committee in July 2026. A recommendation is not a rule, and none is on the bulks list.
Kisspeptin-10No, it stays restricted.The only peptide still in 503A Category 2, the list pharmacies should not compound from.
GHK-CuNot by injection.Non-injectable routes back in Category 1 from 14 May 2026. The injectable route is not covered by the HHS draft.
CJC-1295, ipamorelin, AOD-9604, thymosin alpha-1No, after negative committee votes.FDA's advisory committee voted against each in late 2024.
RetatrutideNo, and no prescription option exists.Investigational, not approved, and not in the HHS draft.

Each status comes from our Category 2 tracker, the July 2026 committee vote and the compound pages. For the GLP-1s, the dated sequence is on the FDA and compounded GLP-1 page.

What the HHS draft policy changes

On 30 October 2026 HHS published a draft enforcement discretion policy for 503A compounding with six peptides, BPC-157, TB-500 and MOTS-c among them. Under it, a state-licensed pharmacy could compound one of them on a patient-specific prescription, from a registered manufacturer with a valid certificate of analysis, with set labelling. The comment period closed on 13 November 2026.

Three limits matter. It is a draft, so the pharmacy route it describes does not exist until it is final. Enforcement discretion is not approval, and not a listing on the bulks list. And it does not cover research-use-only products. A vial sold online for laboratory use stays what it was.

Compounded peptides for sale online

Search "compounded peptides for sale" and two kinds of offer come back. One is a telehealth visit that ends in a prescription a pharmacy fills. That can be legal, for an eligible ingredient. The other is a vial you add to a cart with no prescription. That is not a compounded peptide, whatever the page calls it.

FDA's position is that a "research use only" label does not decide what a product is. When the seller markets it for people, FDA treats it as an unapproved new drug, and its warning letters so far have gone to sellers. States act too. Ohio's Board of Pharmacy says research-use-only drugs are unlawful for prescriber clinics and med spas to possess, Louisiana's Act 374, in force from 1 August 2026, stops state boards from prohibiting peptide compounding from sources that comply with federal compounding law. It does not change which ingredients are eligible. The state peptide laws page has the detail.

Compounded peptides near me: checking a pharmacy

A local or online pharmacy is checked the same way. Four questions cover most of it:

  • Which pharmacy fills it? A clinic that will not name its "pharmacy partner" fails here. Look the pharmacy up on your state board of pharmacy.
  • 503A or 503B? A 503B facility should appear on FDA's list of registered outsourcing facilities.
  • Which eligibility route? Ask how the ingredient qualifies: approved-drug component, USP monograph or the bulks list. "It's compounded" is not an answer.
  • Does a licensed prescriber see you? A clinician licensed in your state, not an intake form on its own. Our four checks for a peptide clinic go further.

Outside a pharmacy, two more pages help: how to vet a peptide supplier and how to get peptides tested. Products sold as research use only are not FDA-approved drugs, and a passing test does not make one safe to use. Is it legal to buy peptides? covers personal import and the other channels.

Peptide AI is building a marketplace with two ways to buy: on a prescription through licensed telehealth, for what can legally be prescribed, or from vetted suppliers with an independent lab report you read before you order. It is not open yet. Early access is here.

Questions people ask

Are compounded peptides FDA approved?

No. A compounded preparation is not an FDA-approved drug, whether a 503A pharmacy or a 503B outsourcing facility makes it. No regulator has reviewed it for the use it is prescribed for.

Are compounded peptides legal?

Yes, when a licensed pharmacy compounds them on a prescription from an eligible ingredient: one that is part of an approved drug, has a USP monograph, or is on FDA's 503A bulks list. Most popular peptides are not eligible today.

Can a pharmacy compound BPC-157?

Not yet. BPC-157 is not on the 503A bulks list. HHS's October 2026 draft policy would let a state-licensed pharmacy compound it on a prescription under strict conditions, but it is a draft.

Are compounded peptides the same as research peptides?

No. A compounded peptide is made by a licensed pharmacy or an FDA-registered outsourcing facility under compounding law. A research peptide is sold as a laboratory reagent with no pharmacy and no prescription, and FDA treats it as an unapproved new drug when it is marketed for people.

Is compounded semaglutide or tirzepatide still legal?

Only in narrow cases. FDA declared the tirzepatide shortage resolved on 19 December 2024 and the semaglutide shortage on 21 February 2025, which ended the broad allowance to make copies.

How do I check a compounding pharmacy?

Look up its license on your state board of pharmacy. A 503B outsourcing facility should also appear on FDA's list of registered outsourcing facilities. Then ask which eligibility route the ingredient comes through.

Free on iOS and Android

Log it once. See it all on one timeline.

Doses, food, training, labs, sleep and scans on one timeline. On iOS and Android.

The PeptideAI protocol screen with a weekly GLP-1 dose on it.